Studies that compared overall and/or metastasis-free and/or prostate-specific antigen (PSA) progression-free survival (OS/MFS/PSA-PFS) and/or adverse events (AEs) in nmCRPC patients were considered eligible. Multiple databases were searched for articles published before June 2020. Therefore, we performed network meta-analysis to indirectly compare the efficacy and safety of currently available treatments. However, direct comparative data are not available to inform treatment decisions and/or guideline recommendations. Management of non-metastatic castration-resistant prostate cancer (nmCRPC) has undergone a paradigm shift with next-generation androgen receptor inhibitors.
0 Comments
Leave a Reply. |